XML 35 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue from Contracts with Customers (Tables)
3 Months Ended
Mar. 31, 2021
Revenue from Contracts with Customers  
Summary of product revenue provision and allowance

    

    

Trade

Rebates and

Product

Allowances and

Three months ended March 31, 2021

Incentives (1)

Returns (2)

Chargebacks (3)

Balance at December 31, 2020

$

132,775

$

23,779

$

19,055

Provision related to current period sales

86,716

3,730

21,002

Changes in estimate related to prior period sales

(441)

Credits/payments made

(75,442)

(14,964)

(23,853)

Balance at March 31, 2021

$

143,608

$

12,545

$

16,204

    

Trade

Rebates and

Product

Allowances and

Three months ended March 31, 2020

Incentives (1)

Returns (2)

Chargebacks (3)

Balance at December 31, 2019

$

129,901

$

27,648

$

14,020

Provision related to current period sales

83,573

3,406

18,770

Changes in estimate related to prior period sales

1,131

49

Credits/payments made

(73,075)

(698)

(18,625)

Balance at March 31, 2020

$

141,530

$

30,356

$

14,214

(1)

Provisions for rebates and incentives includes managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Consolidated Condensed Balance Sheets.

(2)

Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets.

(3)

Provisions for trade allowances and chargebacks include fees for distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s Condensed Consolidated Balance Sheets.

Schedule of disaggregation of revenue

Three months ended March 31, 

2021

2020

Xtampza ER

$

35,409

    

$

31,507

Nucynta Products(1)

52,312

45,004

Total product revenues, net

$

87,721

$

76,511

(1) For the three months ended March 31, 2021, the Company recognized Nucynta IR and Nucynta ER product revenues, net of $30,526 and $21,786, respectively. For the three months ended March 31, 2020, the Company recognized Nucynta IR and Nucynta ER product revenues, net of $27,970 and $17,034, respectively.